migalastat HCl

DRUG7 trials

Sponsors

Amicus Therapeutics

Conditions

Fabry Disease

Phase 2

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

CompletedNCT00214500

Amicus TherapeuticsFabry Disease

Start: 2006-01-02End: 2008-01-29Updated: 2018-10-30

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

CompletedNCT00283933

Amicus TherapeuticsFabry Disease

Start: 2006-05-09End: 2008-03-12Updated: 2018-09-07

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

CompletedNCT00283959

Amicus TherapeuticsFabry Disease

Start: 2006-06-27End: 2008-05-08Updated: 2018-10-31

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

CompletedNCT00304512

Amicus TherapeuticsFabry Disease

Start: 2006-09-07End: 2008-05-09Updated: 2018-10-03

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

TerminatedNCT00526071

Amicus TherapeuticsFabry Disease

Start: 2007-09-17End: 2012-09-08Updated: 2018-10-03

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

CompletedNCT01196871

Amicus TherapeuticsFabry Disease

Start: 2011-02-02End: 2012-10-09Updated: 2018-12-19

Unknown Phase

A Study of Patients With Fabry Disease (US Specific)

RecruitingNCT06906367

Amicus TherapeuticsFabry Disease

Start: 2026-02-13End: 2032-06-01Target: 450Updated: 2026-03-13

Related Papers

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

UNC Libraries2019-08-184 citations

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

PLoS ONE2015-08-0762 citations

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.

2012-11-2469 citations